Literature DB >> 23558628

Bettering BCG: a tough task for a TB vaccine?

William Bishai1, Zuri Sullivan, Barry R Bloom, Peter Andersen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23558628     DOI： 10.1038/nm.3153

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response.

Authors:  Philip T Liu; Steffen Stenger; Huiying Li; Linda Wenzel; Belinda H Tan; Stephan R Krutzik; Maria Teresa Ochoa; Jürgen Schauber; Kent Wu; Christoph Meinken; Diane L Kamen; Manfred Wagner; Robert Bals; Andreas Steinmeyer; Ulrich Zügel; Richard L Gallo; David Eisenberg; Martin Hewison; Bruce W Hollis; John S Adams; Barry R Bloom; Robert L Modlin
Journal:  Science       Date:  2006-02-23       Impact factor: 47.728

2.  Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.

Authors:  Thomas J Scriba; Michele Tameris; Nazma Mansoor; Erica Smit; Linda van der Merwe; Katya Mauff; E Jane Hughes; Sizulu Moyo; Nathaniel Brittain; Alison Lawrie; Humphrey Mulenga; Marwou de Kock; Sebastian Gelderbloem; Ashley Veldsman; Mark Hatherill; Hendrik Geldenhuys; Adrian V S Hill; Gregory D Hussey; Hassan Mahomed; Willem A Hanekom; Helen McShane
Journal:  J Infect Dis       Date:  2011-06-15       Impact factor: 5.226

3.  Induction of direct antimicrobial activity through mammalian toll-like receptors.

Authors:  S Thoma-Uszynski; S Stenger; O Takeuchi; M T Ochoa; M Engele; P A Sieling; P F Barnes; M Rollinghoff; P L Bolcskei; M Wagner; S Akira; M V Norgard; J T Belisle; P J Godowski; B R Bloom; R L Modlin
Journal:  Science       Date:  2001-02-23       Impact factor: 47.728

4.  Modeling the role of public transportation in sustaining tuberculosis transmission in South Africa.

Authors:  Jason R Andrews; Carl Morrow; Robin Wood
Journal:  Am J Epidemiol       Date:  2013-02-18       Impact factor: 4.897

5.  Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses.

Authors:  Rosane M B Teles; Thomas G Graeber; Stephan R Krutzik; Dennis Montoya; Mirjam Schenk; Delphine J Lee; Evangelia Komisopoulou; Kindra Kelly-Scumpia; Rene Chun; Shankar S Iyer; Euzenir N Sarno; Thomas H Rea; Martin Hewison; John S Adams; Stephen J Popper; David A Relman; Steffen Stenger; Barry R Bloom; Genhong Cheng; Robert L Modlin
Journal:  Science       Date:  2013-02-28       Impact factor: 47.728

6.  An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis.

Authors:  Matthew P R Berry; Christine M Graham; Finlay W McNab; Zhaohui Xu; Susannah A A Bloch; Tolu Oni; Katalin A Wilkinson; Romain Banchereau; Jason Skinner; Robert J Wilkinson; Charles Quinn; Derek Blankenship; Ranju Dhawan; John J Cush; Asuncion Mejias; Octavio Ramilo; Onn M Kon; Virginia Pascual; Jacques Banchereau; Damien Chaussabel; Anne O'Garra
Journal:  Nature       Date:  2010-08-19       Impact factor: 49.962

7.  The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity.

Authors:  Rolf Billeskov; Tara T Elvang; Peter L Andersen; Jes Dietrich
Journal:  PLoS One       Date:  2012-06-29       Impact factor: 3.240

8.  MVA.85A boosting of BCG and an attenuated, phoP deficient M. tuberculosis vaccine both show protective efficacy against tuberculosis in rhesus macaques.

Authors:  Frank A W Verreck; Richard A W Vervenne; Ivanela Kondova; Klaas W van Kralingen; Edmond J Remarque; Gerco Braskamp; Nicole M van der Werff; Ariena Kersbergen; Tom H M Ottenhoff; Peter J Heidt; Sarah C Gilbert; Brigitte Gicquel; Adrian V S Hill; Carlos Martin; Helen McShane; Alan W Thomas
Journal:  PLoS One       Date:  2009-04-15       Impact factor: 3.240

9.  Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.

Authors:  Michele D Tameris; Mark Hatherill; Bernard S Landry; Thomas J Scriba; Margaret Ann Snowden; Stephen Lockhart; Jacqueline E Shea; J Bruce McClain; Gregory D Hussey; Willem A Hanekom; Hassan Mahomed; Helen McShane
Journal:  Lancet       Date:  2013-03-23       Impact factor: 79.321
  9 in total
  10 in total

Review 1.  Tuberculosis vaccines - perspectives from the NIH/NIAID Mycobacteria vaccine testing program.

Authors:  Angelo A Izzo
Journal:  Curr Opin Immunol       Date:  2017-07-24       Impact factor: 7.486

2.  Host-directed therapy of tuberculosis based on interleukin-1 and type I interferon crosstalk.

Authors:  Katrin D Mayer-Barber; Bruno B Andrade; Sandra D Oland; Eduardo P Amaral; Daniel L Barber; Jacqueline Gonzales; Steven C Derrick; Ruiru Shi; Nathella Pavan Kumar; Wang Wei; Xing Yuan; Guolong Zhang; Ying Cai; Subash Babu; Marta Catalfamo; Andres M Salazar; Laura E Via; Clifton E Barry; Alan Sher
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

Review 3.  Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis.

Authors:  Shunsuke Sakai; Katrin D Mayer-Barber; Daniel L Barber
Journal:  Curr Opin Immunol       Date:  2014-08       Impact factor: 7.486

4.  The Secreted Protein Rv1860 of Mycobacterium tuberculosis Stimulates Human Polyfunctional CD8+ T Cells.

Authors:  Vijaya Satchidanandam; Naveen Kumar; Sunetra Biswas; Rajiv S Jumani; Chandni Jain; Rajni Rani; Bharti Aggarwal; Jaya Singh; Mohan Rao Kotnur; Anand Sridharan
Journal:  Clin Vaccine Immunol       Date:  2016-04-04

Review 5.  Harnessing local and systemic immunity for vaccines against tuberculosis.

Authors:  P C L Beverley; S Sridhar; A Lalvani; E Z Tchilian
Journal:  Mucosal Immunol       Date:  2013-11-20       Impact factor: 7.313

6.  Commentary: Bettering BCG: a tough task for a TB vaccine?

Authors:  Brahm S Srivastava; Vipul K Singh; Vivek K Kashyap; Ranjana Srivastava; Arshad Khan; Chinnaswamy Jagannath
Journal:  Front Immunol       Date:  2019-09-12       Impact factor: 7.561

Review 7.  Unmet needs in respiratory diseases : "You can't know where you are going until you know where you have been"--Anonymous.

Authors:  Christopher Chang
Journal:  Clin Rev Allergy Immunol       Date:  2013-12       Impact factor: 8.667

Review 8.  The ongoing challenge of latent tuberculosis.

Authors:  H Esmail; C E Barry; D B Young; R J Wilkinson
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2014-05-12       Impact factor: 6.237

9.  Correlation of phenotypic profiles using targeted proteomics identifies mycobacterial esx-1 substrates.

Authors:  Matthew M Champion; Emily A Williams; Richard S Pinapati; Patricia A DiGiuseppe Champion
Journal:  J Proteome Res       Date:  2014-08-25       Impact factor: 4.466

10.  Heterologous Boosting With Listeria-Based Recombinant Strains in BCG-Primed Mice Improved Protection Against Pulmonary Mycobacterial Infection.

Authors:  Si-Jing Liu; Si-Cheng Tian; Yun-Wen Zhang; Tian Tang; Ju-Mei Zeng; Xiao-Yong Fan; Chuan Wang
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.